Company
OPUS Genetics
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of IRDs and other retinal and refractive disorders.
Also known as Opus Genetics, Inc
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Legal name
- Opus Genetics, Inc
- opusgtx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company’s mission is to design therapies to address the underlying genetic causes of severe retinal disorders that deliver durable vision improvement for patients.
Funding snapshot
- Total raised
- $46.9MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $25.8M2024-10-22
Funding rounds
- Round, 2024
- $25.8M2024-10-22, SEC form D sold, 11 investors
- Round, 2020
- $21.1M2020-11-05, SEC form D sold, 18 investors
Products
- Other
- OPGx-BEST1
Loading relationship preview